Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.53 |
| ▸ | PTGES | O14684 | 5/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20296307 | 0.93 | HDAC6 (0.48) | HDAC6PTGESPTGS2NPC1RAB9A | |
| SCHEMBL28821899 | 0.93 | HDAC6 (0.48) | HDAC6PTGESPTGS2NPC1RAB9A | |
| SCHEMBL20296780 | 0.87 | HDAC6 (0.45) | HDAC6PTGESPTGS2NPC1RAB9A | |
| SCHEMBL28821900 | 0.87 | HDAC6 (0.49) | HDAC6PTGESHRH3 | |
| SCHEMBL20296414 | 0.86 | HDAC6 (0.45) | HDAC6PTGESPTGS2NPC1RAB9A | |
| SCHEMBL20296328 | 0.86 | RAB9A (0.52) | HDAC6PTGESPTGS2RAB9AMGLL | |
| SCHEMBL28821901 | 0.86 | HRH3 (0.48) | HDAC6PTGESHRH3 | |
| SCHEMBL3468711 | 0.85 | HRH3 (0.52) | HDAC6PTGESPTGS2HRH3 | |
| SCHEMBL22227676 | 0.85 | CNR2 (0.50) | HDAC6 | |
| SCHEMBL20296248 | 0.84 | KDM4E (0.51) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | HDAC6 303/4885PTGES 200/4885PTGS2 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.